These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14757767)

  • 21. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
    Thomson JM; Distler AM; Bonomo RA
    Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors.
    Ke W; Sampson JM; Ori C; Prati F; Drawz SM; Bethel CR; Bonomo RA; van den Akker F
    Antimicrob Agents Chemother; 2011 Jan; 55(1):174-83. PubMed ID: 21041505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1.
    Nukaga M; Bethel CR; Thomson JM; Hujer AM; Distler A; Anderson VE; Knox JR; Bonomo RA
    J Am Chem Soc; 2008 Sep; 130(38):12656-62. PubMed ID: 18761444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of tazobactam with Staphylococcus aureus PC1 beta-lactamase: a molecular modelling and enzyme kinetics study.
    Denny BJ; Toomer CA; Lambert PA
    Microbios; 1994; 78(317):245-57. PubMed ID: 8078414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
    Totir MA; Cha J; Ishiwata A; Wang B; Sheri A; Anderson VE; Buynak J; Mobashery S; Carey PR
    Biochemistry; 2008 Apr; 47(13):4094-101. PubMed ID: 18324783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance.
    Thomson JM; Distler AM; Prati F; Bonomo RA
    J Biol Chem; 2006 Sep; 281(36):26734-44. PubMed ID: 16803899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase.
    Thomas VL; Golemi-Kotra D; Kim C; Vakulenko SB; Mobashery S; Shoichet BK
    Biochemistry; 2005 Jul; 44(26):9330-8. PubMed ID: 15981999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
    [No Abstract]   [Full Text] [Related]  

  • 29. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
    Totir MA; Padayatti PS; Helfand MS; Carey MP; Bonomo RA; Carey PR; van den Akker F
    Biochemistry; 2006 Oct; 45(39):11895-904. PubMed ID: 17002290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avibactam and inhibitor-resistant SHV β-lactamases.
    Winkler ML; Papp-Wallace KM; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3700-9. PubMed ID: 25691639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276.
    Caniça MM; Caroff N; Barthélémy M; Labia R; Krishnamoorthy R; Paul G; Dupret JM
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1323-8. PubMed ID: 9624468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.
    Drawz SM; Bethel CR; Hujer KM; Hurless KN; Distler AM; Caselli E; Prati F; Bonomo RA
    Biochemistry; 2009 Jun; 48(21):4557-66. PubMed ID: 19351161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cloning and sequencing of the gene encoding Toho-2, a class A beta-lactamase preferentially inhibited by tazobactam.
    Ma L; Ishii Y; Ishiguro M; Matsuzawa H; Yamaguchi K
    Antimicrob Agents Chemother; 1998 May; 42(5):1181-6. PubMed ID: 9593147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
    Danelon G; Mascaretti O; Radice M; Power P; Calcagno ML; Mata EG; Gutkind G
    J Antimicrob Chemother; 1998 Feb; 41(2):313-5. PubMed ID: 9533481
    [No Abstract]   [Full Text] [Related]  

  • 36. Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.
    Pattanaik P; Bethel CR; Hujer AM; Hujer KM; Distler AM; Taracila M; Anderson VE; Fritsche TR; Jones RN; Pagadala SR; van den Akker F; Buynak JD; Bonomo RA
    J Biol Chem; 2009 Jan; 284(2):945-53. PubMed ID: 18955486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structures of the molecular class A β-lactamase TEM-171 and its complexes with tazobactam.
    Grigorenko VG; Petrova TE; Carolan C; Rubtsova MY; Uporov IV; Pereira J; Chojnowski G; Samygina VR; Lamzin VS; Egorov AM
    Acta Crystallogr D Struct Biol; 2022 Jul; 78(Pt 7):825-834. PubMed ID: 35775982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
    Therrien C; Kotra LP; Sanschagrin F; Mobashery S; Levesque RC
    FEBS Lett; 2000 Mar; 470(3):285-92. PubMed ID: 10745083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ligand-dependent disorder of the Omega loop observed in extended-spectrum SHV-type beta-lactamase.
    Sampson JM; Ke W; Bethel CR; Pagadala SR; Nottingham MD; Bonomo RA; Buynak JD; van den Akker F
    Antimicrob Agents Chemother; 2011 May; 55(5):2303-9. PubMed ID: 21357298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single amino acid substitution between SHV-1 beta-lactamase and cefotaxime-hydrolyzing SHV-2 enzyme.
    Barthélémy M; Péduzzi J; Ben Yaghlane H; Labia R
    FEBS Lett; 1988 Apr; 231(1):217-20. PubMed ID: 3129309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.